Uncategorized

Bayer ends multi-year M&A drought with up to $2.45B Perfuse buy

Published

3 hours ago

on

For $300 million upfront, Bayer is purchasing Perfuse Therapeutics to advance an eye implant for glaucoma and diabetic retinopathy, marking the company’s first pharma acquisition since 2021.

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version